Drug General Information
Drug ID	D09UZL
Former ID	DNCL003786
Drug Name	TAK-063
Indication	Schizophrenia [ICD9: 295; ICD10:F20]		Phase 2	[525237]
Company	Takeda
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Phosphodiesterase 10A (PDE10A)	Target Info	Inhibitor	[544471]
KEGG Pathway	Purine metabolism
	Morphine addiction
PathWhiz Pathway	Purine Metabolism
Reactome	cGMP effects
	G alpha (s) signalling events
References
Ref 525237	ClinicalTrials.gov (NCT02477020) A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia.
Ref 544471	Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor. PLoS One. 2015; 10(3): e0122197.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.